Merck's tulisokibart fails a Phase 2 trial in a rare lung disease, but hits its primary endpoint in hidradenitis suppurativa.
August 4, 2026 06:30 AM EDT
Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in a rare lung disease
Merck said the anti-TL1A antibody at the center of its $10.8 billion Prometheus Biosciences acquisition failed a mid-stage trial for a rare type of lung …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Merck's tulisokibart hits Phase 3 primary endpoint in ulcerative colitis, a first win for anti-TL1A drugs and the $10.8B…
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV…
Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.
